Company intelligence / Profile preview

Exacis Biotherapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Exacis Biotherapeutics developed preclinical-stage engineered NK and T cell therapies from iPSCs using proprietary mRNA-based, virus-free reprogramming and gene-editing technologies. These next-generation off-the-shelf cell therapies demonstrated promising in vitro features, such as improved tumor-killing and immune stealth, but do not have clinical trial results to date. The full platform and pipeline were acquired by Eterna Therapeutics in 2023.[2][6]

Therapeutic areas: Oncology
Modalities: Induced pluripotent stem cell derived therapyCell therapyNK cell therapyT cell receptor engineered T cell therapymRNA-based drugs
Industry: Biotech

Partnerships

Factor Bioscience (mRNA technology in-licensing)CCRM (manufacturing and investment, 2021)[5]

Beyond the preview

Go deeper on Exacis Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exacis Biotherapeutics.

Explore the full profile